TW201350116A - Pharmaceutical composition for treating a disease related to survival motor neuron protein expression, promoting reagent for survival motor neuron protein expression and use of triptolide for manufacturing a medicament for treating a disease related to s - Google Patents

Abstract

The invention provides a pharmaceutical composition for treating a disease related to survival motor neuron protein expression, including: an effective mount of triptolide, wherein a formula of the triptolide is shown as Formula (I): ; and a pharmaceutically acceptable carrier or salt.

Description

A pharmaceutical composition for treating diseases associated with the expression of motor neuron survival proteins, a promoter of motor neuron survival protein expression, and triptolide for the preparation of therapeutic and motor neuron survival protein expression Use of the drug for the disease

The present invention relates to a pharmaceutical composition for treating a disease associated with the expression of a survival motor neuron protein (SMN), and in particular to a medicament for treating a disease associated with the expression of a motor neuron survival protein A composition comprising triptolide as an active ingredient, wherein the triptolide has an effect of increasing the performance of a surviving protein of a motor neuron.

In humans, there is a telomeric copy of the motor neuron 1 (SMN1) gene and several centromeric copies of the motor neuron 2 (SMN2) gene. The SMN1 and SMN2 genes encode 90% and 10% full-length survival motor neuron (FL-SMN), respectively. In general, an effective FL-SMN protein maintains the survival of motor neurons. The FL-SMN protein is ubiquitously expressed and is located in both the cytoplasm and the nucleus. In the nucleus, SMN binds to Gemin2-8 by tight protein-protein interactions to form a stable multiplex protein complex called gems (Liu and Dreyfuss, 1996), which is in spliceosomal ribosome (spliceosomal) Small nuclear ribonucleoproteins, snRNPs) play an essential role in the assembly (Meister et al., 2002; Eggert et al., 2006; Neuenkirchen et al., 2008; Talbot and Davies, 2008). In the composition of the SMN complex, both Gemin2 and Gemin3 interact directly and stably with SMN (Todd et al., 2010). Jie The relationship between SMN and Gemin2 is greater than any other composition of the SMN complex (Ogawa et al., 2007). Down-regulation of the interaction of SMN complexes can result in decreased amounts of SMN proteins and motor neuron degeneration (Friesen et al., 2001; Gubitz et al., 2004; Yong et al., 2004; Morris, 2008; Chari et Al., 2009).

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by degeneration of α-motor neurons in the anterior horn of the spinal cord. Muscle paralysis and muscular atrophy. In general, SMAs are classified into three types based on age of onset, severity, and clinical motor function tests. The most severe to mild classifications are: first type (Werdnig-Hoffmann disease), second type (moderate) and third type (Kugelberg-Welander) Disease)). In addition, there are two additional types, type 4 (adult onset with very mild symptoms) and type 0 (severe symptoms of prenatal morbidity leading to early neonatal death) (Dubowitz, 1999; Russman, 2007; Lunn and Wang, 2008). SMA is caused by homozygous disruption and loss of SMN1 gene function due to deletion or mutation. More than 98% of SMA patients have lost function of the SMN1 gene, but will always maintain at least one SMN2 gene replication (Monani, 2005).

However, until today, there is still no effective drug or treatment to treat diseases associated with motor neuron survival protein deficiency, especially if there is no effective drug or treatment that can slow or reverse in SMA. Neuronal degeneration. Therefore, there is a need for a novel drug that is effective in treating diseases associated with the performance of motor neuron survival proteins.

The present invention provides a pharmaceutical composition for treating a disease associated with the expression of a living neuron survival protein, comprising: an effective amount of triptolide as an active ingredient, the molecular formula of the triptolide being as shown in formula (I) : And a pharmaceutically acceptable carrier or salt.

The invention also provides an accelerator for the expression of surviving proteins of motor neurons, including triptolide as an active ingredient, and the molecular formula of the triptolide is as shown in formula (I):

The present invention also provides a pharmaceutical use of triptolide for the preparation of a disease associated with the performance of a surviving protein of a motor neuron, the formula of which is represented by the formula (I):

The above and other objects, features and advantages of the present invention will become more apparent from

In a first aspect of the present invention, the present invention provides a pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein using triptolide as a main active ingredient, which has an increased motor nerve The function of the metastable protein is expressed, and the molecular formula of the above triptolide is as shown in formula (I):

The pharmaceutical composition of the present invention for treating a disease associated with the expression of a motor neuron survival protein may include, but is not limited to, an effective amount of triptolide and a pharmaceutically acceptable carrier or salt, wherein Triptolide is an active ingredient that increases the expression of surviving proteins in motor neurons.

Triptolide, a biologically active diterpene lactone originally derived from Tripterygium wilfordii Hook.F. The triptolide used in the pharmaceutical composition of the present invention may be one plant or artificially synthesized, and is not particularly limited.

Herein, the term "disease related to the expression of surviving proteins of motor neurons" means a disease whose cause is directly related to the amount of surviving protein expression of motor neurons, or is it a disease whose pathogenesis involves the survival of motor neurons. Protein expression. Examples of diseases associated with motoneuron survival protein expression may include, but are not limited to, spinal muscular atrophy, amyotrophic lateral sclerosis, and motor neuron damage. In one implementation In one example, the above-mentioned disease associated with the expression of a motor neuron surviving protein is spinal muscular atrophy. Further, the above spinal muscular atrophy may include the first type, the second type, and/or the third type of spinal muscular atrophy, and is not particularly limited.

Triptolide in the compositions of the invention has the ability to increase the performance of motor neuron survival proteins. In one embodiment, triptolide in vitro or in vivo has the ability to increase the performance of motor neuron survival proteins. In addition, triptolide has the ability to increase the transcriptional capacity of full-length motor neuron survival gene 2 and exon 7 deficiency of motor neuron survival gene 2. Moreover, the above triptolide has the ability to increase the expression of Gemin2 protein and/or Gemin3 protein, and simultaneously the Gemin2 protein increased in the nucleus and the motor neuron survival protein form a motor neuron survival protein complex, also called a nuclear Point (nuclear gem).

In the pharmaceutical composition of the present invention for treating a disease associated with the expression of a motor neuron survival protein, the aforementioned pharmaceutically acceptable carrier may include, but is not limited to, a solvent, a dispersion medium, a coating (coating) ), antibacterial and antifungal agents and first-class osmotic pressure and absorption delaying agents and the like are compatible with pharmaceutical administration. For different modes of administration, the pharmaceutical compositions can be formulated into a dosage form using conventional methods.

Further, the above pharmaceutically acceptable salts may include, but are not limited to, salts including inorganic cations, for example, alkali metal salts such as sodium, potassium or amine salts, alkaline earth gold salts such as magnesium and calcium salts, A salt of a divalent or tetravalent cation such as a zinc, aluminum or zirconium salt. In addition, it may also be an organic salt such as dicyclohexylamine salt, methyl-D-glucosamine, an amine acid salt such as arginine, lysine, histidine, glutamine. .

Administration of the pharmaceutical compositions of this invention may be by oral, parenteral, by inhalation spray or by implantation of an implanted reservoir. Non-oral may include subcutaneous, intracutaneous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal. Intrathecal, intralesional injection and perfusion techniques.

Forms of oral ingredients can include, but are not limited to, tablets, capsules, emulsions, aqueous suspensions, dispersions, and solutions.

In addition, in a second aspect of the present invention, the present invention provides a motor neuron survival protein promoter which has triptolide as an active ingredient and has an effect of enhancing the performance of a motor neuron survival protein, and Tripterygium The molecular formula of the prime is as shown in formula (I):

The above-mentioned motor neuron survival protein promoter may include, but is not limited to, an effective amount of triptolide, wherein triptolide is for increasing exercise An active component of neuronal survival protein expression. The triptolide used in the accelerator of the present invention may be derived from a plant or artificially synthesized, and is not particularly limited.

The triptolide of the motor neuron survival protein promoter of the present invention has an ability to increase the performance of surviving proteins of motor neurons. In one embodiment, triptolide in vitro or in vivo has the ability to increase the performance of motor neuron survival proteins. In addition, triptolide has the ability to increase the transcription of full-length motor neuron survival gene 2 and exon 7 deficiency of motor neuron survival gene 2. Further, the above triptolide has the ability to increase the expression of Gemin2 protein and/or Gemin3 protein. At the same time, the Gemin2 protein added to the nucleus and the motor neuron survival protein form a motoneuron survival protein complex, which is also called a nuclear point.

In one embodiment, the motor neuron survival protein promoter of the present invention can be applied to the treatment of diseases associated with motor neuron survival proteins. The above-mentioned disease associated with the expression of the surviving protein of the motor neuron means a disease whose cause is directly related to the expression of the surviving protein of the motor neuron, or, a disease whose pathogenesis involves the expression of the surviving protein of the motor neuron. Examples of diseases associated with motoneuron survival protein expression may include, but are not limited to, spinal muscular atrophy, amyotrophic lateral sclerosis, and motor neuron damage. In one embodiment, the above-described disease associated with performance of a motor neuron surviving protein is spinal muscular atrophy. The above spinal muscular atrophy may include type I, type 2, and/or type 3 spinal muscular atrophy, and is not particularly limited.

In a third aspect of the present invention, the present invention provides a use of triptolide for the preparation of a medicament for treating a disease associated with performance of a motor neuron survival protein, and the molecular formula of triptolide is as defined in formula (I) Shown as follows:

Herein, the above-mentioned disease meaning related to the expression of the survival protein of the motor neuron is defined as a disease whose cause is directly related to the expression of the survival protein of the motor neuron, or, a disease whose pathogenesis involves the survival of the motor neuron. Protein expression. Examples of diseases associated with motoneuron survival protein expression may include, but are not limited to, spinal muscular atrophy, amyotrophic lateral sclerosis, and motor neuron damage. In one embodiment, the above-described disease associated with performance of a motor neuron surviving protein is spinal muscular atrophy. The above spinal muscular atrophy may include type I, type 2, and/or type 3 spinal muscular atrophy, and is not particularly limited.

It has been confirmed in the present invention that triptolide has an ability to increase the expression of surviving proteins of motor neurons. In one embodiment, triptolide in vitro or in vivo has the ability to increase the performance of motor neuron survival proteins. In addition, triptolide has the ability to increase the transcription of full-length motor neuron survival gene 2 and exon 7 deficiency of motor neuron survival gene 2. Moreover, the above triptolide has the ability to increase the expression of Gemin2 protein and/or Gemin3 protein, and simultaneously the Gemin2 protein increased in the nucleus and the motor neuron survival protein form a motor neuron survival protein complex, also called a nuclear point.

[Examples] A. Method Cell culture

NSC34, mouse neuroblastoma, N18TG2 and mouse embryonic spinal cord motor neuron cell lines (Rizzardini et al., 2006) were cultured as described in the previous literature. Briefly, cells were grown in supplemented with 10% heat-deactivated fetal calf serum (fetal bovine serum, FBS) and antibiotics ^{(100 U.mL -1 penicillin and 100 mg.mL} -1 streptomycin (streptomycin)) of the Modified in Dulbecco's modified Eagle's medium (DMEM). The cells were cultured at 37 ° C in a humidified atmosphere of 5% CO ₂ until the cells were confluent. The medium was changed every 3 days and the pooled cells were subcultured with trypsin solution every 3-5 days. The following experiment was performed in a state where 80% of the cells were full.

Human SMA fibroblast cell lines were established from SMA patient sections with informed consent and prepared as described in the previous literature (Yuo et al., 2008). Informed consent was recognized by the institutional review board (KMUH-IRB-990122) of Kaohsiung Medical University Chung-Ho Memorial Hospital. Maintain fibroblasts with 10% FBS, 100 U. mL ^-1 penicillin (penicillin) with 100 μg. mL ^- l streptomycin in DMEM/F12 medium. The cells were maintained at 37 ° C under humid air containing 5% CO ₂ .

2. Cell survival analysis

Cell viability was achieved by using 3-(4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bromide (3-(4,5-dimethylthiazol-2-yl)- The quantitative colorimetric assay of 2,5-diphenyltetrazolium bromide (MTT) was measured to show the mitochondrial activity of viable cells. The cells were placed in 96-well plates and cultured at different concentrations of triptolide. After 24 hours, the cells were 0.1 mg. The final concentration of MTT at mL ^-1 was incubated at 37 °C for 3 hours. The reaction was terminated by the addition of 100 μL of dimethyl sulfoxide (DMSO). The amount of MTT formazan product was determined by measuring the absorbance at 560 nm using a microplate reader.

3. Apoptosis analysis by annexin V

The cells that encountered apoptosis were detected by double staining with Annexin V-FITC/propidium iodide (PI) (Rizzardini et al.). Briefly, cells attached to a plastic plate were collected by 0.25% trypsin and washed twice with cold PBS. The cell mass is 1 × 10 ⁶ cells. The concentration of mL ^-1 was suspended in 1 time of binding buffer solution (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl ₂ ). Thereafter, cells were cultured with Annexin V-FITC and PI for 15 minutes (22-25 ° C) in the dark. The stained cells were immediately analyzed by a Coulter CyFlow® Cytometer (Partec, Germany). Annexin V-positive cells are considered to be apoptotic cells.

4. Animal and triptolide treatment

SMA-like (Smn ^-/- SMN2) mice were generated as described in the previous literature (Hsieh-Li et al., 2000). All the animals used in the present invention and all the steps regarding the use of the animals were certified by the Animal Care and Use Committee of Kaohsiung Medical University (certification identification: 98096). Briefly, the heterozygous mouse Smn was knocked out - human SMN2 transgenic mice (Smn ^+/- SMN2 ^+/- ) and C57BL/6 mice (purchased from the National Laboratory Animal Breeding and Research Center, Taiwan) backcross (backcross). After purification of the genetic background greater than six generations, Smn ^+/- SMN2 ^+/- mice were obtained which produced SMA-like mice (Tsai et al., 2008). Mice were genotyped by PCR analysis of the tail DNA. Animals are allowed to eat food, water freely, and live in ambient and controlled lighting (lighting between 07:30 and 19:30).

Age-matched animals were divided into five experimental groups: wild type (WT, Smn ^+/+ SMN2 ^-/- ) group; SMA type 3 mouse group; vehicle-treated SMA type III mice Group (accept 5% DMSO in physiological saline); 0.01 or 0.1 mg. Kg ^-1 . Day ^-1 of triptolide (dissolved in 5% DMSO/physiological saline) intraperitoneally injected group of SMA type 3 mice. Survival and body weight were monitored daily during the experiment.

After sacrifice of the animal, the brain, spinal cord and gastrocnemius muscle of the mouse are obtained. Immediately, all tissues will be radioimmunized immediately The radioimmunoprecipitation (RIPA) buffer solution was homogenized and the supernatant was collected after centrifugation. The amount of protein was determined prior to Western blot analysis.

5. Survival analysis and weight development

Five-day-old mice received 0.1 mg via a 30-gauge (gauge) 1-inch injection needle via intraperitoneal injection. Kg ^-1 . Day ^-1 of triptolide. The date of birth is indicated as postnatal day (P)1. The control group received only an equal volume of carrier. The daily weight was measured at P1.

6. Western ink dot analysis

The cells or tissues are homogenized in a cell lysis buffer (Thermo). Protein concentration was determined by Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA, USA). Each lane was loaded with 20 μg of protein, which was then separated by SDS-PAGE and transferred to a polyvinyl difluoride membrane by immunoblotting. Non-specific combination blocking at room temperature with 5% BSA in Tris Buffered saline Tween (TBST) (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20) Block for 1 hour, and then overnight culture at 4 ° C with one of the following specific primary antibodies: mouse monoclonal anti-SMN (1:5000), rabbit polyclonal anti-Gemin2 H-100 (1:500) Rabbit anti-Gemin3 H-145 (1:500), rabbit anti-SUV39H1 (1:1000), rabbit anti-EZH2 (1:1000), mouse anti-β-acting Protein (1:10000). The membrane was incubated with secondary antibody for 1 hour at room temperature, and then borrowed Enhanced chemiluminescence was determined by exposure to a BioMax MR negative (Kodak). For nuclear protein detection, the nuclear extract was isolated using a Nuclear Extraction Kit (Rochester, NY, USA) according to the instruction manual.

7. Quantitative analysis of message RNA (messenger RNA, mRNA)

For quantitative real-time PCR (qPCR) experiments, mRNA was isolated from fibroblasts and purified, after necessary treatment, homogenized with TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and then cyanogenic bismuth sulfonate Extraction by acid guanidinium thiocyanate-phenol-chloroform extraction. Reverse transcription was performed using the Reverse Transcription System kit (Promega, Madison, WI, USA) according to the manufacturer's recommended procedure. 1 μg of total RNA (total RNA) was reverse transcribed into cDNAs. qPCR was used to quantify full-length SMN2 (FL-SMN2) and SMN2 Δ7 transcript levels. qPCR was performed on a ABI PRISM 7500 Sequence Detector System (Applied Biosystems, Foster City, CA, USA) using Power SYBR Green PCR Master Mix (Applied Biosystems). Select primers to bind to SMN exon 7 (5'-GAAGGTGCTCACATTCCTTAAAT-3') (SEQ ID NO: 1) and SMN exon 8 (5'-ATCAAGAAGAGTTACCCATTCCA-3') (SEQ ID NO: 2 In order to amplify the FL-SMN2 transcript, and select primers to bind to SMN exon 5 (5'-CCACCACCCCACTTACTATCA-3') (SEQ ID NO: 3) and SMN exon 6/exon 8 border (5'-GCTCTATGCCAGCATTTCCATA-3') (SEQ ID NO: 4) to amplify the truncated SMN2 Δ7 transcript (Riessland et al., 2006). The relative amounts of transcripts were calculated using a threshold cycle (Ct) method by comparing SMN and GAPDH transcripts according to the manufacturer's protocol. The results were normalized as the ratio between the relative amounts of transcripts in the treated and untreated samples. The qPCR reaction of each sample was performed in three replicates and the experiment was repeated at least three times.

8. Immunofluorescence staining and nuclear gems counting

Immunofluorescence staining is based on general procedures. Briefly, human SMA fibroblasts are grown on a glass chamber slides. After treatment, cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS. After blocking with 2% BSA in PBS, the cells were cultured overnight at 4 °C with mouse monoclonal anti-SMN antibody and rabbit polyclonal anti-Gemin2 H-100 antibody. Alexa Fluor 555 goat anti-mouse IgG was then added to Alexa Fluor 488 goat anti-rabbit IgG di and anti-culture for 1 hour. 4',6-diamidino-2-phenylindole (DAPI) nucleic acid staining confirmed the location of gems. The slides were fixed and sealed prior to observation with a conjugated focal laser scanning microscope (FluoView 1000; Olympus, Center Valley, PA, USA). The total of every 100 cells was analyzed by staining gems.

9. Data analysis

Survival was analyzed by taking a Kaplan-Meier curve and a log-rank test for the Bonferroni post hoc test for multiple comparisons. The body weight curve was assessed by taking Tukey's post-mortem comparison test for multiple comparison ANOVA. Statistical analysis of protein levels and real-time PCR data was performed by Dunnett's by taking all pairwise comparisons of ANOVA. Data are shown as mean ± standard deviation. Probability values ( P ) of less than 0.05 were considered significant in all experiments. All data were analyzed using the Statistical Package for Social Sciences (SPSS, Version 14.0, Chicago, IL, USA).

10. Materials

Triptolide and MTT were obtained from Sigma-Aldrich (St. Louis, MO, USA). DMEM, Ham's F-12 Medium, FBS, penicillin, amphotericin B and streptomycin were obtained from Invitrogen. All materials used for SDS-PAGE were obtained from Bio-Rad. Rabbit antibodies against Gemin2, Gemin3 and SUV39H1 and all secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit antibodies against EZH2 were obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-SMN mouse antibodies were obtained from BD Bioscience (San Jose, CA, USA). The anti-beta-actin mouse antibody was obtained from Sigma-Aldrich. All other chemicals were purchased from Sigma Chemical Co.

B. Results 1. Increase the protein level of SMN, Gemin2 and Gemin3 at a pM concentration of triptolide in a motor neuron-like cell line NSC34

The effect of triptolide (0.01-1 pM) on the regulation of SMN protein was first tested by using NSC34 cells. The cells were treated with vehicle (0.001% DMSO in secondary water) and triptolide (0.01, 0.1 and 1 pM) for 24 hours. The protein extract was then subjected to SDS-PAGE and the expression of SMN, Gemin2, Gemin3 and β-actin was analyzed by Western blotting. The change in the degree of SMN, Gemin2, and Gemin3 normalized by β-actin was quantified and expressed as a percentage of the vehicle group. The results for SMN and Gemin2, Gemin3 are shown in Figures 1A and 1B, respectively. Columns represent the mean ± standard deviation from three independent experiments. ^* P < 0.05, ^** P < 0.01 and ^*** P < 0.001 relative to the vehicle group (using ANOVA followed by Dunnett's assay).

The results indicate that triptolide significantly regulates the extent of SMN protein compared to cells treated with vehicle (0.001% DMSO in secondary water) (Fig. 1A). The effect of triptolide on the composition of the SMN complex (SMN complex), the performance of Gemin2 and Gemin3 was investigated. As shown in Figure 1B, triptolide significantly increased the performance of Gemin2 and Gemin3.

2. Increase the degree of SMN protein in triplicin at pM concentration in human SMA fibroblasts

The effect of triptolide on the regulation of SMN protein expression in human SMA fibroblasts was further explored by treating fibroblasts from three different types of SMA patients with triptolide. Fibroblasts were treated with triptolide (0.01, 0.1 and 1 pM) for 24 hours. The protein was extracted and subjected to SDS-PAGE. Thereafter, the protein expression of SMN and β-actin was measured by Western blotting. The change in the degree of SMN protein normalized by β-actin was quantified and expressed as a percentage of the vehicle group. Western blot analysis results for fibroblasts from SMA patients of the first type, the second type, and the third type are shown in Figures 2A, 2B, and 2C, respectively. Quantitative results for the extent of SMN protein from fibroblasts of SMA patients of the first, second and third types are shown in Figure 2D. Columns represent the mean ± standard deviation from three independent experiments. ^* P < 0.05, ^** P < 0.01 and ^*** P < 0.001 relative to the vehicle group (using ANOVA followed by Dunnett's assay).

The results indicated that triptolide significantly upregulated the extent of SMN protein in all three types of SMA fibroblasts compared to vehicle (0.001% DMSO in secondary water) (2A-D) ).

3. Triptolide increases the expression of Gemin2 and Gemin3 and the number of nuclear gems containing SMN in SMA fibroblasts

Next, the effect of triptolide on the performance of the SMN complex was investigated in three different types of SMA fibroblasts.

Fibroblasts were treated with triptolide (0.01, 0.1 and 1 pM) for 24 hours. Protein expression of Gemin2, Gemin3 and β-actin was analyzed by Western blotting. The change in the degree of Gemin2 and Gemin3 protein normalized by β-actin was quantified. The results for fibroblasts from SMA patients of the first type, the second type, and the third type are shown in Figures 3A, 3B, and 3C, respectively. Columns represent the mean ± standard deviation from three independent experiments. ^* P < 0.05, ^** P < 0.01 and ^*** P < 0.001 relative to the vehicle group (using ANOVA followed by Dunnett's assay). As shown in Figures 3A-C, triptolide significantly increased the performance of Gemin2 and Gemin3 in all three types of SMA fibroblasts.

In addition, the number of nuclear gems is related to the degree of SMN protein, and it is significantly reduced in patients with SMA. To further determine that the increased amount of SMN is indeed a functional protein, a conjugated focal microscope was used to analyze the intracellular location of SMN in triptolide-treated cells. Human SMA type III fibroblasts were treated with triptolide (1 pM) for 24 hours. The total number of SMN-containing nuclear gems per 100 cells was observed by conjugated focal length microscopy with anti-SMN- and anti-Gemin2-specific antibodies. Alexa Fluor 555 goat anti-mouse IgG (red) and Alexa Fluor 488 goat anti-rabbit IgG (green) were used as secondary antibodies. DAPI (blue) is used for nuclear staining. Figure 4A shows the staining results, and Figure 4B shows the total number of nuclear sites containing SMN and Gemin2 bound in the nucleus. The histograms represent the mean ± standard deviation from three independent experiments. ^* P <0.05 vs. vehicle group (ANOVA followed by Dunnett's assay). As shown in Figures 4A-B, treatment with triptolide (1 pM) significantly increased the number of nuclear sites compared to vehicle treated SMA fibroblasts.

4. Triptolide increases full-length SMN2 (FL-SMN2) transcripts in human SMA fibroblasts

To determine whether an increase in the SMN protein induced by triptolide resulted in an increase in the amount of SMN protein containing exon 7, a qPCR using a primer set that distinguishes two variants (FL-SMN2 and SMN2 Δ7) was used to test Leigong. Tomatotropin was used to test the effect of triptolide on SMN2 transcription.

Cells were treated with triptolide (0.01, 0.1 and 1 pM) for 24 hours. The FL-SMN2/SMN2 Δ7 ratio normalized by GAPDH was quantified. All data are shown as mean ± standard deviation from any of the three independent experiments in the form of arbitrary units of GAPDH. The results for fibroblasts from the third type of SMA patients are shown in Figures 5A and 5B, while the results for fibroblasts from the first type of SMA patients are shown in Figure 5C. In the 5D picture. ^* P < 0.05 and ^** P < 0.01 relative to the vehicle group (using ANOVA followed by Dunnett's assay).

The FL-SMN2 transcript increased to a greater extent than the SMN2 Δ7 transcript. The ratio of FL-SMN2 to SMN2Δ7 was significantly increased to 1.6 times after treatment of SMA type III fibroblasts with triptolide (Figs. 5A and 5B), rather than treatment of SMA with triptolide After type I fibroblasts (Fig. 5C and Fig. 5D). These results indicate that triptolide increases the extent of SMN protein, in part because of the activation of the SMN2 transcript. They also indicate that triptolide promotes the insertion of exon 7, at least in SMA type III fibroblasts.

5. No cytotoxic effects were detected at the SMN2 activation concentration

Experiment with Rayleigh using MTT analysis and Annexin V/PI staining The cytotoxicity of sinomenine at the concentration of activated SMN2.

SMA fibroblasts were treated with vehicle and triptolide (0.01, 0.1, 1, 10 and 100 pM) for 24 hours, respectively. Cell viability was determined by MTT assay and the results are shown in Figure 6A. The change in cell viability was shown as a percentage of the vehicle group. Apoptosis was analyzed by flow cytometry using Annexin V/PI staining. Apoptosis of each group was shown as an apoptosis index, which was evaluated by calculating the percentage of apoptotic cells (Annexin V-positive cells), and the results are shown in Fig. 6B. Cycloheximide (CHX) 10 mg. mL ^{-1 was} used as a positive control group for inducing apoptosis. Columns represent the mean ± standard deviation from three independent experiments. ^*** P < 0.001 vs. vehicle group (using ANOVA followed by Dunnett's assay).

As shown in Figures 6A and 6B, neither vehicle nor triptolide was cytotoxic and did not increase cell death.

6. Triptolide increases the degree of SMN protein in neurons and muscle tissue of SMA-like mice

Since the above in vitro data showed that triptolide can significantly increase SMA protein in human SMA fibroblasts, the effect of triptolide on type III SMA mice was further investigated.

Mice (Smn ^-/- SMN2) were injected daily with vehicle or triptolide (0.01 or 0.1 mg.kg ^-1 .day ^-1 , ip) for one week. The brain was isolated from the wild type (WT, Smn ^+/+ SMN2 ^-/- ) (n=5) and the third type SMA group (n=5 per group) treated with vehicle or triptolide. Spinal cord and gastrocnemius. The total protein from various tissues was extracted separately, and the SMN protein content was determined by Western blotting, and the results are shown in Fig. 7A. Further, the SMN proteins in the brain, spinal cord, and gastrocnemius muscle were quantified, and the results are shown in Fig. 7B. Beta-actin (for the brain and spinal cord) or GAPDH (for the gastrocnemius) was used as a loading control group. ^* P < 0.05 and ^** P < 0.01 relative to the vehicle group. Relative to the wild type group, ### P < 0.001 (using ANOVA followed by Dunnett's assay).

There were no significant changes in body weight and mortality in all groups during this in vivo experiment (data not shown). As shown in Figures 7A and 7B, all tissues from the SMA mouse group treated with triptolide showed a significant increase in the extent of SMN protein, especially at higher doses (0.1 mg.kg ^-1 . Day ^-1 ) When using. Most importantly, these in vivo data indicate that triptolide increases the SMN protein in the two major tissues involved in SMA conditions, the spinal cord and muscle.

7. Triptolide treatment improves the survival rate of SMA-like mice and reduces the weight loss of SMA mice

Previous literature has shown that SMA mice 5 days after birth (P5) show a clear manifestation of this disease (Le et al., 2005; Avila et al., 2007), and P5 to P13 are the best drugs for SMA mice. The minimal window (Narver et al., 2008). In this experiment, SMA mice (Smn ^-/- SMN2) and wild type were intraperitoneally injected with triptolide (0.1 mg.kg ^-1 ) or vehicle daily from 5 days after birth to 18 days after birth. Mice (WT, Smn ^+/+ SMN2 ^-/- ) were monitored for survival and body weight. Survival of mice treated with triptolide (n=15) or vehicle (n=13) was shown by Kaplan-Meier survival curves and the results are shown in Figure 8A. P < 0.001 (logarithmic level check). Figure 8B shows SMA mice treated with triptolide (n=15) or vehicle (n=13) and treated with triptolide (n=20) or vehicle (n=20) The weight of wild type mice. ^* P < 0.05 and ^** P < 0.01 relative to the SMA mice treated with the vehicle (using ANOVA followed by Tukey's assay).

As shown in Figure 8A, the survival rate of triptolide-treated mice increased by 3.63 days compared with vehicle-treated mice (treated by triptolide, the survival rate was 11.86 ± 1.25 days; Treatment, survival rate was 8.23 ± 1.45 days), which showed an increase in their lifespan of 44.16%. One of the first clinical symptoms of SMA is weight loss. SMA mice were significantly underweight at 5 days of age (P5) (Le et al., 2005). Vehicle-treated SMA mice showed significant body weight differences (1.90 ± 0.37 g vs. 2.65 ± 0.70 g, Figure 8B) compared to wild-type mice at 5 days of age. However, triptolide-treated SMA mice showed a slight increase in body weight compared to vehicle-treated SMA mice. The growth curves at ages of 10 to 12 showed significant differences.

Each of the above experiments clearly shows that triptolide can increase the performance of SMN protein in vitro and in vivo . Triptolide can increase the performance of Gemin2 and Gemin3, which are composed of SMN complexes, and the increased SMN protein forms a SMN complex with Gemin2 and forms a nuclear gem in the nucleus. Furthermore, triptolide is not cytotoxic at concentrations that activate SMN2. Therefore, it is clear from the above experimental results that triptolide can be used for the treatment of diseases related to the performance of motor neuron survival proteins, particularly SMA.

While the present invention has been described in its preferred embodiments, the present invention is not intended to limit the invention, and the present invention may be modified and modified without departing from the spirit and scope of the invention. The scope of protection is subject to the definition of the scope of the patent application.

Figures 1A and 1B show the effect of triptolide on the extent of SMN protein and the composition of SMN complexes in NSC34 cells, respectively.

Figures 2A through 2D show that in human SMA fibroblasts from different types of SMA patients, the degree of SMN protein of triptolide is up-regulated.

Figures 3A to 3C show the effect of triptolide on the expression of Gemin2 and Gemin3 proteins in SMN complexes in human SMA fibroblasts from different types of SMA patients.

Figures 4A and 4B show the effect of triptolide on the number of nuclear and nuclear sites containing SMN and Gemin2 in the human SMA type III fibroblast cell line, respectively.

Figures 5A and 5B show FL-SMN2 and SMN2 Δ7 transcripts as determined by quantitative real-time PCR in SMA type III fibroblasts.

Panels 5C and 5D show FL-SMN2 and SMN2 Δ7 transcripts as determined by quantitative real-time PCR in SMA Type I fibroblasts.

Figure 6A shows that triptolide has no cytotoxic effects on human SMA type III fibroblasts.

Figure 6B shows the results of measuring apoptosis of human SMA type III fibroblasts treated with triptolide by flow cytometry using Annexin V/PI staining.

Figures 7A and 7B show upregulation of SMN protein in the brain, spinal cord and muscle of SMA mice treated with triptolide.

Figures 8A and 8B show the survival rate of triptolide-enhanced SMA mice and the decrease in body weight of SMA mice, respectively.

<110> A pharmaceutical composition for treating a disease associated with the expression of a motor neuron survival protein, an agent for the expression of a motor neuron survival protein, and a triptolide for preparing a disease associated with the performance of a motor neuron survival protein Use of drugs

<120> Kaohsiung Medical University

<130> 0911-A52772TW

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Introduction

<400> 1

<210> 2

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Introduction

<400> 2

<210> 3

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> Introduction

<400> 3

<210> 4

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Introduction

<400> 4

Claims (27)

A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein, comprising: an effective amount of triptolide as an active ingredient, the molecular formula of the triptolide being as shown in formula (I): And a pharmaceutically acceptable carrier or salt. A pharmaceutical composition for treating a disease associated with performance of a motor neuron surviving protein according to claim 1, wherein the disease associated with performance of a motor neuron surviving protein includes spinal muscular atrophy, muscular atrophy Lateral sclerosis or motor neuron damage. A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein according to claim 1, wherein the disease associated with performance of a motor neuron survival protein is spinal muscular atrophy. A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein according to claim 3, wherein the spinal muscular atrophy comprises a first type, a second type, and/or a third type of spinal cord Sexual muscle Atrophy. A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein according to claim 1, wherein the triptolide has an ability to increase the performance of a motor neuron survival protein. A pharmaceutical composition for treating a disease associated with performance of a motor neuron surviving protein according to claim 1, wherein the triptolide has an increase in full-length motor neuron survival gene 2 and exon 7 lack of exercise The ability of neurons to survive the transcription of gene 2. A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein according to claim 1, wherein the triptolide has an ability to increase the expression of Gemin2 protein and/or Gemin3 protein. A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein according to claim 7, wherein the increased Gemin2 protein and the motor neuron survival protein form a motor neuron survival protein in the nucleus Complex. A pharmaceutical composition for treating a disease associated with performance of a motor neuron survival protein according to claim 1, wherein the triptolide has an ability to promote formation of a nuclear dot in a nucleus. An accelerator for the expression of surviving proteins of motor neurons, including triptolide as an active ingredient, the molecular formula of the triptolide is as shown in formula (I): An agent for the expression of a motor neuron surviving protein according to claim 10, wherein the motoneuron surviving protein exhibits an agent for treating a disease associated with performance of a motor neuron surviving protein. An agent for the expression of a motor neuron surviving protein according to claim 11, wherein the disease associated with the expression of a motor neuron surviving protein includes spinal muscular atrophy, amyotrophic lateral sclerosis or motor neurons damage. An agent for expressing a motor neuron surviving protein according to claim 11, wherein the disease associated with the expression of a motor neuron surviving protein is spinal muscular atrophy. An agent for the expression of a motor neuron surviving protein according to claim 13, wherein the spinal muscular atrophy comprises a first type, a second type, and/or a third type of spinal muscular atrophy. An agent for expressing a motor neuron survival protein according to claim 10, wherein the triptolide has increased transcription of a full-length motor neuron survival gene 2 and an exon 7 deficiency motor neuron survival gene 2 ability. An agent for the expression of a motor neuron surviving protein according to claim 10, wherein the triptolide has the ability to increase the expression of the Gemin2 protein and/or the Gemin3 protein. An enhancer for the expression of a motor neuron surviving protein according to claim 16, wherein the increased Gemin2 protein and the motor neuron surviving protein form a motor neuron survival protein complex in the nucleus. An accelerator for the expression of a motor neuron surviving protein according to claim 10, wherein the triptolide has the ability to promote nuclear formation in a nucleus. A use of triptolide for the preparation of a medicament for treating a disease associated with the expression of a survival protein of a motor neuron, the formula of which is represented by the formula (I): The use of triptolide as described in claim 19, for the preparation of a medicament for treating a disease associated with the expression of a motor neuron survival protein, wherein the disease associated with the expression of a motor neuron survival protein comprises a spinal muscular muscle Atrophy, amyotrophic lateral sclerosis or motor nerve Meta damage. The use of triptolide as described in claim 19, for the preparation of a medicament for treating a disease associated with the expression of a motor neuron survival protein, wherein the disease associated with the expression of a motor neuron survival protein is a spinal muscular muscle Atrophy. The use of triptolide as described in claim 21, for the preparation of a medicament for treating a disease associated with performance of a motor neuron survival protein, wherein the spinal muscular atrophy comprises a first type, a second type, and / or third type of spinal muscular atrophy. Use of triptolide as described in claim 19, for the preparation of a medicament for treating a disease associated with the expression of a motor neuron survival protein, wherein the compound of formula (I) has increased motor neuron survival The ability of protein to express. Use of triptolide as described in claim 19, for the preparation of a medicament for treating a disease associated with performance of a motor neuron surviving protein, wherein the compound of formula (I) has increased full length motor neurons Survival gene 2 and exon 7 lack the ability to transcribe motor neuron survival gene 2. The use of triptolide as described in claim 19, for the preparation of a medicament for treating a disease associated with performance of a motor neuron survival protein, wherein the compound of formula (I) has an increased Gemin2 protein and/or Or the ability of Gemin3 protein to express. The use of triptolide as described in claim 25, for the preparation of a medicament for the treatment of a disease associated with the expression of a motor neuron survival protein, wherein the increased Gemin2 protein and movement in the nucleus Neuronal survival proteins form a motor neuron survival protein complex. The use of triptolide as described in claim 19, in the preparation of a medicament for treating a disease associated with the performance of a motor neuron survival protein, wherein the triptolide has a function of promoting nuclear formation in a nucleus ability.